These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20553075)

  • 21. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
    Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble Fas level and cancer mortality: findings from a nested case-control study within a large-scale prospective study.
    Tamakoshi A; Nakachi K; Ito Y; Lin Y; Yagyu K; Kikuchi S; Watanabe Y; Inaba Y; Tajima K;
    Int J Cancer; 2008 Oct; 123(8):1913-6. PubMed ID: 18688865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery.
    Lee DY; Yang DH; Kang CW; Kim SJ; Joo CU; Cho SC; Kim JS
    J Korean Med Sci; 1997 Feb; 12(1):32-9. PubMed ID: 9142657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between serum levels of superoxide dismutase activity and subsequent risk of cancer mortality: Findings from a nested case-control study within the Japan Collaborative Cohort Study.
    Pham TM; Fujino Y; Nakachi K; Suzuki K; Ito Y; Watanabe Y; Inaba Y; Tajima K; Tamakoshi A; Yoshimura T;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():69-73. PubMed ID: 20553085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-related serum levels of insulin-like growth factor-I, -II and IGF-binding protein-3 following myocardial infarction.
    Reeves I; Abribat T; Laramee P; Jasmin G; Brazeau P
    Growth Horm IGF Res; 2000 Apr; 10(2):78-84. PubMed ID: 10931745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of association between serum transforming growth factor-beta 1 and cancer mortality risk in a nested case-control study in Japan.
    Lin Y; Nakachi K; Ito Y; Kikuchi S; Tamakoshi A; Yagyu K; Watanabe Y; Inaba Y; Tajima K;
    Asian Pac J Cancer Prev; 2009; 10(2):273-8. PubMed ID: 19537896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer.
    Serrano ML; Romero A; Cendales R; Sánchez-Gómez M; Bravo MM
    Biomedica; 2006 Jun; 26(2):258-68. PubMed ID: 16925098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth and insulin-like growth factors (IGFs) in children with insulin-dependent diabetes mellitus at the onset of disease: evidence for normal growth, age dependency of the IGF system alterations, and presence of a small (approximately 18-kilodalton) IGF-binding protein-3 fragment in serum.
    Cianfarani S; Bonfanti R; Bitti ML; Germani D; Boemi S; Chiumello G; Boscherini B
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4162-7. PubMed ID: 11095448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts.
    Wolpin BM; Michaud DS; Giovannucci EL; Schernhammer ES; Stampfer MJ; Manson JE; Cochrane BB; Rohan TE; Ma J; Pollak MN; Fuchs CS
    Br J Cancer; 2007 Jul; 97(1):98-104. PubMed ID: 17533398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer.
    Lukanova A; Zeleniuch-Jacquotte A; Lundin E; Micheli A; Arslan AA; Rinaldi S; Muti P; Lenner P; Koenig KL; Biessy C; Krogh V; Riboli E; Shore RE; Stattin P; Berrino F; Hallmans G; Toniolo P; Kaaks R
    Int J Cancer; 2004 Jan; 108(2):262-8. PubMed ID: 14639613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between serum levels of superoxide dismutase activity and subsequent risk of lung cancer mortality: Findings from a nested case-control study within the Japan Collaborative Cohort Study.
    Pham TM; Fujino Y; Ando M; Suzuki K; Nakachi K; Ito Y; Watanabe Y; Inaba Y; Tajima K; Tamakoshi A; Yoshimura T;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():75-9. PubMed ID: 20553086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
    Oh JC; Wu W; Tortolero-Luna G; Broaddus R; Gershenson DM; Burke TW; Schmandt R; Lu KH
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):748-52. PubMed ID: 15159305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women.
    Lukanova A; Toniolo P; Akhmedkhanov A; Biessy C; Haley NJ; Shore RE; Riboli E; Rinaldi S; Kaaks R
    Int J Cancer; 2001 Jun; 92(6):888-92. PubMed ID: 11351312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease.
    Krassas GE; Pontikides N; Kaltsas T; Dumas A; Frystyk J; Chen JW; Flyvbjerg A
    J Clin Endocrinol Metab; 2003 Jan; 88(1):132-5. PubMed ID: 12519841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
    Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death.
    Lin Y; Tamakoshi A; Kikuchi S; Yagyu K; Obata Y; Ishibashi T; Kawamura T; Inaba Y; Kurosawa M; Motohashi Y; Ohno Y
    Int J Cancer; 2004 Jul; 110(4):584-8. PubMed ID: 15122592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers.
    Stolzenberg-Solomon RZ; Limburg P; Pollak M; Taylor PR; Virtamo J; Albanes D
    Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):438-44. PubMed ID: 15006921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.